Nya pengar till svenskledd satsning på nya antibiotika
ENABLE-2 News and media coverage
ENABLE-2 expanding its project portfolio with two new programmes
Antibiotic platform ENABLE-2 welcomes two new programmes: the "Ornicidine" programme, a scientific collaboration between Leiden University in the Netherlands and Queen's University Belfast in Northern Ireland; and the "BamA Inhibitors" programme, based at the German Justus Liebig University Giessen and Fraunhofer IME.
ENABLE-2 crosses the North Sea
ENABLE-2 expands its project portfolio with Strathclyde Minor Groove Binders, a program based in Glasgow and the University of Strathclyde. With this collaboration, the platform takes the step into Europe in its search for new promising antibiotics.
ENABLE-2 Open Call raising international interest
“We welcome the great international interest shown in our platform", states Anders Karlén, coordinator of ENABLE-2 that in a recent call for proposals received applications from six European countries.
Läkemedelsvärlden: Enable-2 får fortsatt finansiering 2023
Anders Karlén in Lif podcast: Antibiotic resistance - the silent pandemic
Anders Karlén, Professor of Computational Medicinal Chemistry and coordinator of ENABLE 2, and Årets läkemedelsprofil (Pharmaceutical Drug Profile of the Year) Enrico Baraldi discuss Antibiotic resistance - the silent pandemic in a new episode of Lif:s Podden. Antibiotic expert Bengt Mattson and Pod host Amy Havenäng, both Lif, also participate in the conversation (note: pod in Swedish)
The Swedish Research Council invests SEK 25 million in ENABLE-2
ENABLE-2 receives continued funding from the Swedish Research Council, now allocating SEK 25 million to the platform's second year of operations. "We are about to open a second call in order to complement our portfolio with additional projects," says Anders Karlén, Coordinator of ENABLE-2 and Professor at Uppsala University.
ENABLE-2 partner Uppsala University publishes patent application
ENABLE-2 partner Uppsala University has published a first patent application on a series of compounds targeting the LpxH enzyme and showing highly potent in vivo activity. These compounds are active against wild-type bacterial cells, including carbapenem-resistant clinical isolates, and show very good efficacy in clearing infections in mouse models.
Anders Karlén guest in Forskarpodden: The Fight Against Antibiotic Resistance
In The Fight against Antibiotic Resistance, the new episode of Forskarpodden, Anders Karlén, Professor and Coordinator of ENABLE-2, and Dan I Andersson, Professor of Medical Bacteriology, discuss the current efforts at Uppsala University to fight the challenges of accelerating antibiotic resistance. (Note: Pod in Swedish)
Akut behov av breda lösningar mot antibiotikaresistens
Luke Odell promoted to Professor of Medicinal Chemistry
ENABLE-2 and The Faculty of Pharmacy congratulates Luke Odell on his promotion to Professor of Medicinal Chemistry at Uppsala University. “Research is a joint effort, so this is a recognition that our entire team can take pride in,” states Luke Odell, leader of ENABLE-2 project QuinGiT.
ENABLE-2 has accepted a new program from Thioredoxin Systems AB
We are happy to announce that ENABLE-2 has accepted a new program to assist Thioredoxin Systems AB in the development of their EbsArgent product.
Researcher profile: Anders Karlén coordinates the combat against the invisible enemy
“As long as disaster does not strike with full force, many prefer to look elsewhere,” says Anders Karlén, Professor of Computer-Aided Drug Design, who after coordinating the European flagship ENABLE now continues the fight against antibiotic-resistant bacteria within the framework of the international platform ENABLE -2.
”Morötter till industrin löser inte bristen på nya antibiotika”
Dagens Medicin, 2022-05-23
ENABLE-2 satsar på fyra projekt om nya antibiotika
Alumnus in focus: Malin Grape is the world's first AMR Ambassador
“Sweden has a very distinctive voice in antibiotic matters that both the EU and the world listen to, and we must use it," states Malin Grape, Swedish ambassador against antimicrobial resistance and alumnus at the Faculty of Pharmacy.
QureTech Bio får stort stöd för fortsatt utveckling av nya antibiotika
Umeåbaserade QureTech Bio AB får stöd av Vetenskapsrådets storsatsning ENABLE-2, som i samarbete med Vinnova även ger små och medelstora företag tillgång till ENABLE-2-plattformen för att fortsätta jakten på nya antibiotika. Plattformen tillhandhåller resurser i form av experimentellt arbete och erfarenhet inom antibiotikautvecklingens tidiga stadier.
ENABLE-2 takes the lead in the pursuit of new antibiotics
The Swedish Research Council's investment in ENABLE-2 has, with support from Vinnova, launched with four projects that are considered very promising in the pursuit for new antibiotics. In the first round of admissions, two projects from Uppsala University, and one each from Linköping University and the biotech company QureTech Bio AB were selected for development.
ENABLE-2 ready to lead continued development of new antibiotics
ENABLE, the EU initiative for antibiotic development led by Uppsala University, will continue its work in ENABLE-2 with financial support from the Swedish Research Council. "An independent committee have chosen between many interesting project proposals and the platform is now entering operational phase," says Anders Karlén, Professor at the Faculty of Pharmacy.
SciLifeLab part of ENABLE-2, an international collaboration to combat antimicrobial resistance
Forskningspengar att söka för nya antibiotika
SEK 25 million to ENABLE-2 and continued development of new antibiotics
ENABLE, the EU initiative for antibiotic development led by Uppsala University, has received SEK 25 million from the Swedish Research Council to start up ENABLE-2. "We are already accepting project proposals and hope that this investment will inspire more financiers," says coordinator Anders Karlén.
Nya pengar till svenskledd satsning på nya antibiotika
Learn more about current & previous events at ENABLE-2